A commercially available non—radioactive DNA labelling kit "enhanced chemiluminescence"(ECL) was evaluated for the diagnosis of falciparum malaria. The results showed that ECL labeled probe successfully det...A commercially available non—radioactive DNA labelling kit "enhanced chemiluminescence"(ECL) was evaluated for the diagnosis of falciparum malaria. The results showed that ECL labeled probe successfully detected as little as 25 pg. Purified DNA of 0.001％ parasitemia of cultured Plasmodium falciparum and did not react with human展开更多
An emerging paradigm shift for disease diagnosis is to rely on molecular characterization beyond traditional clinical and symptom-based examinations. Although genetic alterations and transcription signature were first...An emerging paradigm shift for disease diagnosis is to rely on molecular characterization beyond traditional clinical and symptom-based examinations. Although genetic alterations and transcription signature were first introduced as potential biomarkers, clinical implementations of these markers are limited due to low reproducibility and accuracy. Instead, epigenetic changes are considered as an alternative approach to disease diagnosis. Complex epigenetic regulation is required for normal biological functions and it has been shown that distinctive epigenetic disruptions could contribute to disease pathogenesis. Disease-specific epigenetic changes, especially DNA methylation, have been observed,suggesting its potential as disease biomarkers for diagnosis. In addition to specificity, the feasibility of detecting disease-associated methylation marks in the biological specimens collcted noninvasively,such as blood samples, has driven the clinical studies to validate disease-specific DNA methylation changes as a diagnostic biomarker. Here, we highlight the advantages of DNA methylation signature for diagnosis in different diseases and discuss the statistical and technical challenges to be overcome before clinical implementation.展开更多
文摘A commercially available non—radioactive DNA labelling kit "enhanced chemiluminescence"(ECL) was evaluated for the diagnosis of falciparum malaria. The results showed that ECL labeled probe successfully detected as little as 25 pg. Purified DNA of 0.001％ parasitemia of cultured Plasmodium falciparum and did not react with human
基金supported in part by NIH grants(NS051630, NS079625, MH102690 and NS097206 to P.J.)
文摘An emerging paradigm shift for disease diagnosis is to rely on molecular characterization beyond traditional clinical and symptom-based examinations. Although genetic alterations and transcription signature were first introduced as potential biomarkers, clinical implementations of these markers are limited due to low reproducibility and accuracy. Instead, epigenetic changes are considered as an alternative approach to disease diagnosis. Complex epigenetic regulation is required for normal biological functions and it has been shown that distinctive epigenetic disruptions could contribute to disease pathogenesis. Disease-specific epigenetic changes, especially DNA methylation, have been observed,suggesting its potential as disease biomarkers for diagnosis. In addition to specificity, the feasibility of detecting disease-associated methylation marks in the biological specimens collcted noninvasively,such as blood samples, has driven the clinical studies to validate disease-specific DNA methylation changes as a diagnostic biomarker. Here, we highlight the advantages of DNA methylation signature for diagnosis in different diseases and discuss the statistical and technical challenges to be overcome before clinical implementation.
